(EMAILWIRE.COM, June 24, 2021 ) The report "In Vivo Toxicology Market by Product (Animal Models, Reagents & Kits), Test Type (Chronic, Sub-acute), Toxicity Endpoints (Systemic, Immunotoxicity), Testing Facility (Outsourced, In-house), End User (Academic & Research Institute, CROs) - Forecast to 2025", is projected to reach USD 6.6 billion by 2025, at a CAGR of 5.5% between 2020 and 2025.

Growth Opportunity: Rising demand for humanized animal models
Humanized animal models are important tools for conducting preclinical research to gain insights into human biology. These models are developed through the engraftment of human cells or tissues, leading to the expression of human proteins in animals.

Humanized mice are increasingly being used as models for biomedical research applications, such as cancer, infectious diseases, HIV/AIDS, regenerative medicine, and hepatitis. In March 2019, the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the US Department of Health and Human Services, announced funding for projects to conduct detailed characterization, direct comparisons, and further development of humanized immune system (HIS) mouse models. The need to identify the actual effects of drugs on humans, as well as the growing focus on studying human-specific infections, therapies, and immune responses, is promoting the development and use of humanized animal models

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=105308811

Consumables accounted for the largest share in the in vivo toxicology market in 2019.

Based on the product, Categorized into instruments and consumables. The consumables segment is further categorized into animal models and reagents & kits. Animal models is sub segmented into mice, rat and other animals. The consumables segment accounted for the largest share of the in vivo toxicology market in 2019. The widespread use of reagents & kits in research activities, increase in funds for research projects, and their extensive application in the in vivo toxicology studies are fueling the growth of this segment

Chronic test type accounted for the largest share in the in vivo toxicology market in 2019

Based on test type, Segmented into acute, sub-acute, sub-chronic, and chronic test type. The chronic test type segment is expected to dominate the market during the forecast period. In 2019, the chronic test type segment held the largest share of the market, followed by sub-chronic test type.Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105308811

North America accounted for the largest share of the in vivo toxicology market in 2019.

Based on the region, Segmented into North America, Europe, the Asia Pacific, Latin Ametica and Middle East & Africa. In 2019, North America accounted for the largest share of the market. The large share of the North America region can be attributed to the presence of major players operating in the market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

The major players operating in in vivo toxicology testing market are by Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia), Harbour BioMed (US) among others.